• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非肥胖型炎症性肠病患者的营养不良和炎症状态与非酒精性脂肪性肝病相关:一项回顾性研究。

Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study.

作者信息

Nagata Takahiro, Funakoshi Sadahiro, Morihara Daisuke, Shakado Satoshi, Yokoyama Keiji, Takata Kazuhide, Tanaka Takashi, Fukunaga Atsushi, Yamauchi Ryo, Fukuda Hiromi, Matsuoka Hiroki, Imakiire So, Sakisaka Hideto, Matsuoka Satoshi, Kuno Nobuaki, Abe Koichi, Ishibashi Hideki, Ashizuka Shinya, Hirai Fumihito

机构信息

Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.

出版信息

Intest Res. 2023 Oct;21(4):471-480. doi: 10.5217/ir.2023.00035. Epub 2023 Aug 11.

DOI:10.5217/ir.2023.00035
PMID:37559192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10626015/
Abstract

BACKGROUND/AIMS: The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in patients with IBD.

METHODS

We retrospectively identified and enrolled patients with IBD diagnosed with or without NAFLD by undergoing abdominal computed tomography (CT) at our institution between 2005 and 2020. The primary endpoint was the complication rate of NAFLD in patients with IBD. Secondary endpoints were the clinical characteristics of nonobese patients with IBD and comorbid NAFLD and their association with nutritional and inflammatory parameters.

RESULTS

Twenty-one (21.9%) of 96 eligible patients with IBD also had NAFLD. In nonobese patients (defined as patients with a body mass index <25 kg/m2), C-reactive protein (CRP; P<0.001) and alanine aminotransferase (P=0.018) levels were higher and the albumin level (P=0.005) and prognostic nutritional index (PNI; P=0.002) values were lower in patients with NAFLD than in those without NAFLD. The PNI value was positively correlated (P<0.001) and the CRP level was negatively correlated (P=0.001) with the hepatosplenic ratio. However, in the NAFLD combined group, PNI (P<0.05) and CRP values (P<0.001) were improved over time after CT imaging by continuing IBD treatment.

CONCLUSIONS

Worsening nutritional and inflammatory status in IBD patients is associated with complications of NAFLD. Diagnosis of NAFLD in IBD patients using CT imaging might be useful not only for early detection of NAFLD but also in assessing the need for therapeutic intervention for IBD.

摘要

背景/目的:炎症性肠病(IBD)患者中非酒精性脂肪性肝病(NAFLD)并发症的发生率及细节尚不清楚。本研究旨在阐明IBD患者中NAFLD的特征。

方法

我们回顾性地识别并纳入了2005年至2020年间在我们机构接受腹部计算机断层扫描(CT)诊断为有或无NAFLD的IBD患者。主要终点是IBD患者中NAFLD的并发症发生率。次要终点是IBD合并NAFLD的非肥胖患者的临床特征及其与营养和炎症参数的关联。

结果

96例符合条件的IBD患者中有21例(21.9%)也患有NAFLD。在非肥胖患者(定义为体重指数<25kg/m²的患者)中,NAFLD患者的C反应蛋白(CRP;P<0.001)和丙氨酸转氨酶(P=0.018)水平较高,白蛋白水平(P=0.005)和预后营养指数(PNI;P=0.002)值低于无NAFLD的患者。PNI值与肝脾比呈正相关(P<0.001),CRP水平与肝脾比呈负相关(P=0.001)。然而,在NAFLD合并组中,通过持续进行IBD治疗,CT成像后随时间推移PNI(P<0.05)和CRP值(P<0.001)有所改善。

结论

IBD患者营养和炎症状态的恶化与NAFLD的并发症相关。使用CT成像诊断IBD患者中的NAFLD不仅可能有助于早期发现NAFLD,还可用于评估IBD治疗干预的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/58b382de7e76/ir-2023-00035f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/840e4361c4eb/ir-2023-00035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/2b26e852304f/ir-2023-00035f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/054ec4ac6d46/ir-2023-00035f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/6e61153746b9/ir-2023-00035f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/58b382de7e76/ir-2023-00035f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/840e4361c4eb/ir-2023-00035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/2b26e852304f/ir-2023-00035f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/054ec4ac6d46/ir-2023-00035f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/6e61153746b9/ir-2023-00035f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e666/10626015/58b382de7e76/ir-2023-00035f5.jpg

相似文献

1
Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study.非肥胖型炎症性肠病患者的营养不良和炎症状态与非酒精性脂肪性肝病相关:一项回顾性研究。
Intest Res. 2023 Oct;21(4):471-480. doi: 10.5217/ir.2023.00035. Epub 2023 Aug 11.
2
The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.非酒精性脂肪性肝病对炎症性肠病患者住院结局的影响:全国性分析。
Inflamm Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.
3
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.炎症性肠病患者的非酒精性脂肪性肝病:超越自然史。
World J Gastroenterol. 2019 Oct 7;25(37):5676-5686. doi: 10.3748/wjg.v25.i37.5676.
4
P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.P045:巴西一家公共医疗诊所中炎症性肠病(IBD)患者的非酒精性脂肪性肝病(NAFLD)患病率
Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S11-S12. doi: 10.14309/01.ajg.0000798780.14901.4e.
5
Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.肠道炎症不能预测炎症性肠病患者的非酒精性脂肪性肝病严重程度。
Dig Dis Sci. 2017 May;62(5):1354-1361. doi: 10.1007/s10620-017-4495-0. Epub 2017 Mar 6.
6
Visceral adiposity and inflammatory bowel disease.内脏肥胖与炎症性肠病。
Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9.
7
Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.炎症性肠病患者血清生物标志物与非酒精性脂肪性肝病的发病率及预测因素
Inflamm Bowel Dis. 2016 Aug;22(8):1937-44. doi: 10.1097/MIB.0000000000000832.
8
Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease.原发性硬化性胆管炎对炎症性肠病中的非酒精性脂肪性肝病具有保护作用。
Hum Pathol. 2017 Nov;69:55-62. doi: 10.1016/j.humpath.2017.09.008. Epub 2017 Sep 29.
9
Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.炎症性肠病患者中非酒精性脂肪性肝病的流行病学及危险因素
Inflamm Bowel Dis. 2017 Jun;23(6):998-1003. doi: 10.1097/MIB.0000000000001085.
10
Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.炎症性肠病患者中非酒精性脂肪性肝病的患病率:系统评价和荟萃分析。
Inflamm Bowel Dis. 2021 May 17;27(6):947-955. doi: 10.1093/ibd/izaa189.

引用本文的文献

1
Impact of body mass index on clinical outcomes in intestinal Behçet's disease.体重指数对肠道白塞病临床结局的影响。
Korean J Intern Med. 2025 Jul;40(4):606-615. doi: 10.3904/kjim.2024.349. Epub 2025 Jul 1.
2
Elucidating the association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a focus on systemic inflammation.阐明非酒精性脂肪性肝病与炎症性肠病发病率之间的关联:聚焦全身炎症。
Intest Res. 2025 Jan;23(1):3-5. doi: 10.5217/ir.2024.00204. Epub 2025 Jan 24.
3
Metabolic Disorders and Inflammatory Bowel Diseases.

本文引用的文献

1
Moving computed tomography-based quantification of muscle mass to the mainstream: Validation of a web-based platform to calculate skeletal muscle index in cirrhosis.将基于计算机断层扫描的肌肉质量量化方法推广至主流应用:验证一个用于计算肝硬化患者骨骼肌指数的网络平台
Liver Transpl. 2022 Dec;28(12):1944-1946. doi: 10.1002/lt.26538. Epub 2022 Jul 10.
2
Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.炎症性肠病中MAFLD和肝纤维化风险增加,独立于经典代谢危险因素。
Clin Gastroenterol Hepatol. 2023 Feb;21(2):406-414.e7. doi: 10.1016/j.cgh.2022.01.039. Epub 2022 Feb 3.
3
代谢紊乱与炎症性肠病
Gut Liver. 2025 May 15;19(3):307-317. doi: 10.5009/gnl240316. Epub 2025 Jan 8.
The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease.
炎症性肠病(IBD)中营养不良的另一面:非酒精性脂肪性肝病。
Nutrients. 2021 Aug 13;13(8):2772. doi: 10.3390/nu13082772.
4
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.2012 年至 2017 年全球慢性肝病负担的变化:非酒精性脂肪性肝病的影响日益增加。
Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173. Epub 2020 Oct 27.
5
Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index.日本非酒精性脂肪性肝病的特征性表现,重点关注年龄、性别和体重指数的作用。
Gut Liver. 2020 Sep 15;14(5):537-545. doi: 10.5009/gnl19236.
6
Sarcopenia and fatty liver disease.肌肉减少症与脂肪肝。
Hepatol Int. 2019 Nov;13(6):674-687. doi: 10.1007/s12072-019-09996-7. Epub 2019 Nov 8.
7
Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department.炎症性肠病患者在急诊科就诊时经计算机断层扫描诊断的非酒精性脂肪性肝病患病率
Ann Gastroenterol. 2019 May-Jun;32(3):283-286. doi: 10.20524/aog.2019.0371. Epub 2019 Mar 15.
8
CoreSlicer: a web toolkit for analytic morphomics.CoreSlicer:一种用于分析形态组学的网络工具包。
BMC Med Imaging. 2019 Feb 11;19(1):15. doi: 10.1186/s12880-019-0316-6.
9
Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study.非酒精性脂肪性肝病在炎症性肠病消瘦患者中的病例对照研究。
PLoS One. 2018 Nov 14;13(11):e0206450. doi: 10.1371/journal.pone.0206450. eCollection 2018.
10
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的病因、发病机制及治疗
N Engl J Med. 2017 Nov 23;377(21):2063-2072. doi: 10.1056/NEJMra1503519.